Alumis: Six Officers Sold at $26.37 on a 10% Down Day
Six Alumis executives sold 14,953 shares at $26.37 on August 3, a session where the stock fell 10%, generating roughly $394,000 in combined proceeds per Form 4 filings. With ALMS now at $23.62 and ana
Six ALMS Officers Sold at $26.37 on a 10% Down Day
NEW YORK, August 27 —
Alumis Inc. (ALMS) saw its entire C-suite agree on one thing on August 3: $26.37 was a reasonable price to sell shares into a session where the stock fell 10%. The stock has not recovered. At $23.62, ALMS trades below every one of those exit prices, while the analyst consensus target of $40.33 implies 71% upside.
- Six officers sold 14,953 shares at $26.37 on August 3, generating roughly $394,000 in combined proceeds, per Form 4 filings.
- Alumis holds $500 million in cash against $40 million in debt; TTM operating cash outflow was $351 million.
- The analyst consensus price target of $40.33 implies 71% upside from the current $23.62.
Six Officers, One Price
When six members of a company's C-suite sell at identical prices on a 10% down session, the most charitable read is a scheduled 10b5-1 plan. Alumis develops envudeucitinib, a TYK2 inhibitor in trials for plaque psoriasis and lupus, alongside a CNS-penetrant neuroinflammation program and a thyroid eye disease antibody. With insider ownership at just 0.5% of shares and institutions holding 93.2%, the six executives collectively held little stock before August 3. The simultaneous exit is notable less for its size and more for its unanimity: the CFO, CMO, CSO, CLO, CDO and Chief Business Officer all agreed that price was a reasonable exit while the market repriced lower.
Adequate Runway Is the Optimistic Read
Alumis posted EPS of -$0.79 in the most recent quarter, missing consensus by 11.3%, per its August 13 8-K, a reversal after beating by 10.9% the prior quarter. TTM operating cash outflow stands at $351 million against a $500 million cash balance and $40 million in debt: roughly 17 months of runway at current burn. BlackRock's recent 5.7% stake and a $40.33 analyst consensus target show institutional confidence in envudeucitinib's psoriasis and lupus programs. Whether the August 3 sales reflected routine plan execution or something more deliberate is the question those programs will eventually answer.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ALMS | $3.1B | n/a | +380.1% |
| MBX | $3.2B | n/a | +367.8% |
| MLYS | $2.3B | n/a | +70.2% |
| ABVX | $10.2B | n/a | +46.7% |
| ERAS | $6.7B | n/a | +1112.0% |
| CGON | $7.0B | n/a | +193.5% |
What the Next Readout Must Show
Recent commentary puts ALMS at potentially 33% undervalued, citing positive psoriasis study results; Stifel and Guggenheim were reportedly holding bullish ratings earlier this summer. The gap between that view and management's August 3 exit price narrows or widens on the next clinical readout from envudeucitinib. If Phase data confirms the efficacy signal analysts are pricing in, the coordinated sales look like routine plan execution at an unfortunate moment. If it disappoints, management's timing on a down day will look considerably more prescient. A DCF model of the cash runway offers a useful frame for the risk. Run the free Alumis Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Alumis officers sell shares on August 3?
Six officers, including the CFO, CMO, CSO, CLO, CDO, and Chief Business Officer, sold 14,953 shares at $26.37 on August 3, generating roughly $394,000 in combined proceeds per Form 4 filings. The most charitable read is a scheduled 10b5-1 plan. The stock fell 10% that session and has not recovered, with ALMS now trading at $23.62.
What is Alumis's cash runway?
Alumis holds $500 million in cash against $40 million in debt, with TTM operating cash outflow of $351 million. That works out to roughly 17 months of runway at current burn.
What is the analyst price target for ALMS stock?
The analyst consensus price target of $40.33 implies 71% upside from the current $23.62. Stifel and Guggenheim were reportedly maintaining bullish ratings earlier this summer, and BlackRock recently acquired a 5.7% stake.
What drug does Alumis develop?
Alumis develops envudeucitinib, a TYK2 inhibitor in trials for plaque psoriasis and lupus, alongside a CNS-penetrant neuroinflammation program and a thyroid eye disease antibody.
What were Alumis earnings results?
Alumis posted EPS of -$0.79 in the most recent quarter, missing consensus by 11.3% per its August 13 8-K. That was a reversal after beating by 10.9% the prior quarter.
Six Alumis executives—including the CFO, CMO, and CSO—sold shares simultaneously at $26.37 on August 3, the same session news data shows the stock falling 10%; ALMS now trades at $23.62, roughly 10% below their exit price, while the analyst consensus target sits at $40.33.